govt.fyi
Back to HB 3359
Oklahoma Legislature· HB 3359Second Reading referred to Rules

An act relating to Medicaid coverage, the official text

Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1                   STATE OF OKLAHOMA

2            2nd Session of the 60th Legislature (2026)

3 HOUSE BILL 3359                 By: Williams

4

5

6                   AS INTRODUCED

7   An Act relating to Medicaid coverage; amending

    Section 3, Chapter 331, O.S.L. 2023 (56 O.S. Supp.

8   2025, Section 4003), which relates to biomarker

    testing coverage; making coverage discretionary; and

9   providing an effective date.

10

11

12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13  SECTION 1.      AMENDATORY  Section 3, Chapter 331, O.S.L.

14 2023 (56 O.S. Supp. 2025, Section 4003), is amended to read as

15 follows:

16  Section 4003. A. As used in this section:

17  1. "Biomarker", "biomarker testing", "consensus statement", and

18 "nationally recognized clinical practice guidelines" shall have the

19 same meaning as provided by Section 1 of this act; and

20  2. "Contracted entity" shall have the same meaning as provided

21 by Section 4002.2 of Title 56 of the Oklahoma Statutes.

22  B. The state Medicaid program shall cover biomarker testing in

23 accordance with the requirements provided by this section.

24

    Req. No. 15739                                                 Page 1
1   C. Biomarker testing shall may be covered for the purposes of

2 diagnosis, treatment, appropriate management, or ongoing monitoring

3 of a member's disease or condition when the test is supported by

4 medical and scientific evidence, including, but not limited to:

5   1. Labeled indications for a United States Food and Drug

6 Administration (FDA)-approved or -cleared test;

7   2. Indicated tests for an FDA-approved drug;

8   3. Warnings and precautions on FDA-approved drug labels;

9   4. Centers for Medicare and Medicaid Services (CMS) national

10 coverage determinations or Medicare Administrative Contractor (MAC)

11 local coverage determinations; or

12  5. Nationally recognized clinical practice guidelines and

13 consensus statements.

14  D. Contracted entities under the state Medicaid program shall

15 provide biomarker testing at the same scope, duration, and frequency

16 as the Medicaid program otherwise provides to members.

17  E. If prior authorization is required for biomarker testing,

18 the contracted entity shall approve or deny a prior authorization

19 request and notify the member, the member's provider, and any entity

20 requesting authorization of the service within seventy-two (72)

21 hours for non-urgent requests or within twenty-four (24) hours for

22 urgent requests.

23  F. The member and the member's provider shall have access to

24 clear, readily accessible, and convenient processes to request an

    Req. No. 15739                                                 Page 2
1 exception to a coverage policy for biomarker testing of the state

2 Medicaid program. The process shall be made readily accessible to

3 all participating providers and members online.

4   SECTION 2. This act shall become effective November 1, 2026.

5

6   60-2-15739      TJ  01/04/26

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

    Req. No. 15739                                 Page 3
Every fact on this page links to its source, starting with the official bill record.